Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
+$0.06 today
- Market cap
- $156.01M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
Volume 1.71M
Average 1.12M
ABEO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Abeona Therapeutics Inc.NASDAQ: ABEO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$15.37M, compared with -$10.22M a year earlier. Trailing-twelve-month EBITDA was $73.43M.
Context
- EBITDA amounted to 1350.3% of revenue in FY2025.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$50.66M (-164.5%) for the fiscal year ending Dec 2026, a slowdown from the +238.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$15.37M+17.8% QoQ
- Last fiscal yearDec 2025
- $78.59M+238.8% YoY
- LTMMar 2026
- $73.43M+298.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -50.5% | -109.4% | -58.9 pp |
| 1 year | +238.8% | -164.5% | -403.3 pp |
| 3-year CAGR | — | -24.4% | — |
| 5-year CAGR | +22.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 78.59M USD
- Year-over-year change
- +238.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 78.59M | +238.8% |
| FY2024 | 2024-12-31 | (56.62M) | -12.0% |
| FY2023 | 2023-12-31 | (50.57M) | -47.1% |
| FY2022 | 2022-12-31 | (34.38M) | +55.2% |
| FY2021 | 2021-12-31 | (76.82M) | — |
EBITDA vs competitors
How ABEO compares with its peers on the latest reported figures
- ABEO's LTM Mar 2026 EBITDA of $73.43M is the highest of the 10 companies compared; the peer median is -$72.53M.
- Its year-over-year change of +298.8% is the highest of 10, against a peer median of -3.7%.
- EBITDA amounts to 505.0% of revenue for ABEO, versus a peer median of 257.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $73.43M | +298.8% | — | 505.0% | |
| LTM Mar 2026 | $44.91M | -17.8% | +34.6% | 19.8% | |
| LTM Mar 2026 | -$6.26M | +84.1% | — | 8.8% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$46.14M | +19.2% | — | — |
| LTM Mar 2026 | -$67.53M | -3.7% | — | 148.9% | |
| LTM Mar 2026 | -$72.53M | +7.7% | — | 257.0% | |
| LTM Mar 2026 | -$75.47M | +22.0% | — | 33540.9% | |
| LTM Mar 2026 | -$78.03M | -325.2% | — | — | |
| LTM Mar 2026 | -$79.77M | -33.1% | — | 3956.7% | |
| LTM Mar 2026 | -$112.54M | -37.5% | — | 308.4% | |
| Peer median (excluding ABEO) | -$72.53M | -3.7% | +34.6% | 257.0% | |
Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3M | 1.41M | 3.5M | 0 | 5.82M |
| Cost of Revenue | 0 | 450K | 1.61M | 2.91M | 1.53M |
| Gross Profit | 3M | 964K | 1.9M | (2.91M) | 4.29M |
| Gross Margin | 100.0% | 68.2% | 54.1% | — | 73.7% |
| Research & Development | 38.73M | 28.97M | 31.09M | 34.36M | 26.81M |
| Selling, General & Admin | 21.64M | 17.26M | 19M | 29.85M | 65.03M |
| Operating Expenses | 92.84M | 51.88M | 49.03M | 61.3M | 93.74M |
| Depreciation & Amortization | 4.46M | 4.58M | 3.2M | 2.91M | 3.56M |
| EBITDA | (76.82M) | (34.38M) | (50.57M) | (56.62M) | 78.59M |
| EBITDA Margin | -2560.5% | -2431.6% | -1444.9% | — | 1350.3% |
| Operating Income | (89.84M) | (50.92M) | (47.14M) | (64.21M) | (89.45M) |
| Operating Margin | -2994.5% | -3600.8% | -1346.7% | — | -1536.9% |
| Interest Income | 40K | 431K | 2.12M | 4.25M | 5.56M |
| Interest Expense | 3.66M | 736K | 418K | 4.21M | 3.74M |
| Other Income / Expenses | 4.9M | 11.22M | (7.05M) | 477K | 160.73M |
| Income Before Tax | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.28M |
| Pre-Tax Margin | -2831.2% | -2807.4% | -1548.2% | — | 1224.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 100K |
| Net Income | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.18M |
| Net Margin | -2831.2% | -2807.4% | -1548.2% | — | 1223.1% |
| EPS (Basic) | (21.50) | (5.53) | (2.53) | (1.55) | 1.34 |
| EPS (Diluted) | (21.50) | (5.53) | (2.53) | (1.55) | 1.01 |
| Weighted Avg Shares | 3.94M | 7.86M | 21.38M | 41.05M | 52.95M |
| Weighted Avg Shares (Diluted) | 3.94M | 7.86M | 21.38M | 41.05M | 66.14M |
Abeona Therapeutics Inc.
NASDAQ:ABEO
Intrinsic Alpha fair value
Locked
Current Price
$2.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.